---
title: "Pasithea Therapeutics (KTTA.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KTTA.US/norm.md"
symbol: "KTTA.US"
name: "Pasithea Therapeutics"
parent: "https://longbridge.com/en/quote/KTTA.US.md"
datetime: "2026-05-20T14:06:03.966Z"
locales:
  - [en](https://longbridge.com/en/quote/KTTA.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KTTA.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KTTA.US/norm.md)
---

# Pasithea Therapeutics (KTTA.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.1200 | -0.7917 | -0.4081 | -0.6587 | -1.61 |
| ROE | -20.86% | -119.96% | -88.73% | -105.58% | -102.68% |
| Revenue | - | - | - | - | - |
| Net income | -2.87M | -10.11M | -3.04M | -3.72M | -3.56M |
| Operating income | -4.88M | -6.09M | -3.11M | -3.81M | -3.68M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 56.35M | 60.24M | 13.63M | 17.01M | 14.66M |
| Leverage | 1.03 | 1.09 | 1.12 | 1.12 | 1.13 |
| BVPS | 2.20 | 2.39 | 1.64 | 2.04 | 4.80 |
| Turnover | - | - | - | - | - |
| Cash & STI | 50.40M | 55.16M | 4.12M | 7.22M | 5.34M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | 113564.00 | 117522.00 |
| Net debt | -50.40M | -55.16M | -4.12M | -7.22M | -5.34M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -4.79M | -5.40M | -2.89M | -3.87M | -3.06M |
| Investing CF | - | 11000.00 | - | - | - |
| Financing CF | 750.00 | 56.42M | -116145.00 | 5.74M | 1.47M |
| Free CF | -7.41M | 141139.00 | -2.06M | -2.66M | -1.90M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |